Physician profile
Rajesh Rohatgi
NPI 1932118528
$4,417.53
in general payments reported to CMS, 2019-2025
31 companies · $770 in 2025
The $770 reported for 2025 was more than what a typical Nuclear Cardiology provider received nationally (typical 2025 total: $434).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,248 · 2020: $164 · 2021: $11.81 · 2022: $268 · 2023: $1,054 · 2024: $901 · 2025: $770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,725.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $633.81 | 2020-2025 | Tezspire, Fasenra, Breztri |
| Harmony Biosciences LLC | $374.44 | 2022-2025 | Wakix |
| Mallinckrodt Enterprises LLC | $339.05 | 2019 | |
| Mallinckrodt Hospital Products INC. | $334.20 | 2022-2023 | Acthar |
| Glaxosmithkline, LLC. | $332.57 | 2019-2025 | Shingrix, Nucala |
| Sanofi-Aventis U.S. LLC | $249.74 | 2019 | |
| Mylan Specialty L.P. | $244.94 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $161.66 | 2025 | Dupixent |
| Janssen Pharmaceuticals, INC | $125.00 | 2019 | |
| Merck Sharp & Dohme LLC | $125.00 | 2024 | Capvaxive |
| Lilly USA, LLC | $124.99 | 2024 | Jaypirca |
| Exelixis INC. | $124.97 | 2024 | Cabometyx |
| Sunovion Pharmaceuticals INC. | $124.97 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.95 | 2019 | |
| Axsome Therapeutics, INC. | $124.93 | 2023 | Sunosi |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $122.19 | 2024 | |
| Dexcom, INC. | $109.33 | 2024 | Dexcom G6 Transmitter |
| Gilead Sciences, INC. | $99.60 | 2019-2025 | Veklury |
| Novo Nordisk INC | $85.35 | 2023-2024 | Rybelsus, Ozempic |
| Exact Sciences Corporation | $68.93 | 2023-2024 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $61.33 | 2023-2025 | Aralast, Hyqvia |
| Amgen INC. | $60.15 | 2023-2024 | Tezspire, Repatha |
| Teva Pharmaceuticals USA, INC. | $55.32 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $46.72 | 2022 | |
| Pfizer INC. | $32.31 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $30.97 | 2025 | Purified Cortrophin Gel |
| Grifols USA, LLC | $25.86 | 2023 | Xembify |
| Paratek Pharmaceuticals, INC. | $20.01 | 2024 | Nuzyra |
| Emd Serono, INC. | $18.70 | 2022 | |
| Abbvie INC. | $17.96 | 2023 | Linzess, Viberzi |
| Novartis Pharmaceuticals Corporation | $17.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajesh Rohatgi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.